Tag Archives: chronic kidney disease

Not long ago, diabetes management focused primarily on controlling blood glucose levels. Today, that approach has evolved dramatically as cardiologists and endocrinologists increasingly work together to reduce cardiovascular risk. Thanks to groundbreaking cardiovascular outcome trials (CVOTs), clinicians now understand that treating type 2 diabetes means protecting the heart, kidneys, and …

For years, the treatment of diabetic kidney disease focused primarily on glycemic control and blood pressure management. More recently, SGLT2 inhibitors and GLP-1 receptor agonists have transformed the landscape by reducing kidney disease progression and cardiovascular events. However, another therapeutic class is rapidly gaining recognition. Non-steroidal mineralocorticoid receptor antagonists (MRAs) …

Blood pressure control remains one of the most powerful tools for reducing cardiovascular and kidney complications in people with diabetes. While clinicians have traditionally focused on achieving targets below 140/90 mmHg, recent evidence and the 2026 American Diabetes Association Standards of Care support a more intensive approach for selected high-risk …

Chronic kidney disease (CKD) remains one of the most serious complications associated with diabetes, affecting millions of patients worldwide. While SGLT2 inhibitors have become foundational therapies for protecting kidney function, researchers are increasingly examining whether other drug classes may also slow renal decline. In particular, growing interest surrounds how GLP-1 …

Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease …

As GLP-1 receptor agonists dominate headlines and prescribing trends, many clinicians wonder whether older therapies are losing relevance. However, SGLT2 inhibitors remain foundational in type 2 diabetes care. More importantly, evidence now supports the use of SGLT2 inhibitors and GLP-1 combination therapy in patients at high cardiovascular and renal risk. …

The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …

Diabetes and chronic kidney disease (CKD) are two of the most common chronic illnesses in the world. Both can have serious consequences if left untreated, but proper management can help reduce the risk of further complications. This article will provide an overview of diabetes and CKD, discuss risk factors for …